Combined oral contraception and the risk of venous thromboembolism

Human Reproduction

Volumn 12, Issue 12, 1997, Pages 2595-2598

  Mills, Angela ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTODENE; ORAL CONTRACEPTIVE AGENT;

DRUG SAFETY; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY; THROMBOEMBOLISM;

EID: 0031435694     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/12.12.2595     Document Type: Short Survey

References (23)

1. Bloemenkamp, K.W.M., Rosendaal, F.R., Helmerhorst, F.R. et al. (1995) Enhancement of factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestogen. Lancet, 346, 1593-1596.
2. Bromham, D. and O'Brien, T. (1995) Information for health professionals further to the Committee on Safety of Medicines' advice on the safety of oral contraceptives. [Letter, dated 18 October 1995.] Faculty of Family Planning and Reproductive Health Care and the Family Planning Association, London.
3. Committee on Safety of Medicines (1995) Combined Oral Contraceptives and Thromboembolism. Letter 17 October 1995. Committee on Safety of Medicines, London.
4. Farmer, R.D.T., Lawrenson, R.A., Thompson, C.R. et al. (1997) Population based study of the risk of venous thromboembolism associated with low oestrogen dose oral contraceptives. Lancet, 349, 83-88.
5. Hammerstein, J., Daume, E., Simon, A. et al. (1993) Influences of gestodene and desogestrel components of low dose oral contraceptives on the pharmacokinetics of ethinyl estradiol, on serum CBG and on urinary cortisol annd 6β-hydroxycortisol. Contraception, 47, 263-281.
6. Helmerhorst, F.M., Bloemenkamp, K.W.M., Rosendaal, F.R. and Vandenbroucke, J.P. (1997) Oral contraceptives and thrombotic diseases: risk of venous thromboembolism. Thromb. Haemost., 327-333.
7. Hope, S. (1996) 12% of women stopped taking their pill immediately they heard the CSM's warning. Lancet, 312, 576.
8. Jick, H., Jick, S., Gurewich, V. et al. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet, 346, 1589-1593.
9. Jung-Hoffmann, C. and Kuhl, H. (1989) Interaction with the pharmacokinetics of ethinlyestradiol and progestogens contained in oral contraceptives. Contraception, 40, 299-312.
10. Lancet (1997) Time to act to avoid drug safety scares. [Editorial]. Lancet, 350, 1041.
11. Lewis, M.A., Spitzer, W.O., Heinemann, L.A.J. et al. (19??) [Letter to the editor.] Br. Med. J., 330, 680-681.
12. Mills, A., Wilkinson, C. and Fotherby, K. (1998) Can a change in screening and prescribing practice reduce the risk of venous thromboembolism in women taking the combined oral contraceptive pill? BJFP, in press.
13. Mori (1996) Women' confidence in the pill undermined. [Press release]. Mori, London.
14. Murty, J., Harris, J. and Killick, S. (1996) Television and radio should be used to disseminate important information. Br. Med. J., 312, 1672.
15. Office of National Statistics (1996) Mortality statistics. HMSO Series DH2, 21, 349 and 358.
16. Orme, M., Back, D.J., Ward, S. et al. (1991) The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel. Contraception., 43, 305-316.
17. Rees, C.D., Cox, M. and Clegg, J.B. (1995) World distribution of factor V Leiden. Lancet, 346, 1133.
18. Reijnen, H.B.M. and Atsma, W.J. (1995) Risk is highest during first months of use. [Letter to the editor] Br. Med. J., 311, 1639.
19. Vandenbroucke, J.P., Kosteer, T., Brier, P. et al. (1994) Increased risk of venous thromboembolism in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet, 344, 1453-1457.
20. Vandenbroucke, J.P., van der Meer, J.M., Heimerhorst, F.M. et al. (1996) Factor V Leiden: should we screen oral contraceptive users and pregnant women? Br. Med. J., 313, 1127-1130.
21. Vessey, M.P. (1989) The Jeffcott lecture: an overview of the benefits and risks of combined oral contraceptives. In Mann, R.D. (ed.), Oral Contraceptives and Breast Cancer: The Implications of the Present Findings for Informed Consent and Informed Choice. Parthenon Publishing group, NJ, USA, pp. 121-135.
22. Spitzer, W.O., Lewis, M., Heinemann, L.A.J. et al./Transnational Research Group on oral contraceptives and the health of young women (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders. Br. Med. J., 31, 2:83-88.
23. World Health Organization/Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Effect of different progestogens in low dose oral contraceptives on venous thromboembolic disease. Lancet, 346, 1582-1588.